Gen-Probe Positions Genetic and Pharma Business for Future Growth

Gen-Probe Life Sciences Ltd has completed the consolidation of its Molecular Genetic Services (MGS) business at its newly expanded facilities in Wythenshawe, Manchester, which has increased its footprint from11,000 ft2 to 67,000 ft2 ft. Among other benefits, the expansion of the facility will provide the catalyst for the consolidation and further development of a suite of outsourced genomic services. Gen- Probe Life. The company which provides nucleic acid extraction and array-based services, is intending to move into the R&D stage of drug development providing support to translational

research through the discovery, qualification and validation of biomarkers and IUO assays with the potential for both drug development and companion diagnostic applications. David Scott, senior director, commercial services and Diaclone, said: “We are excited to be implementing this next stage in the strategic development of our pharma services brand. We believe that the potential to identify and develop both genomic and proteomic assays for biomarkers at an early stage presents a real value proposition to biopharmaceutical companies seeking companion diagnostics.”As part of this consolidation, Gen-Probe Life Sciences Ltd has appointed Dr Bob Holt as MGS manager responsible for the growth and development of the MGS business, and Haroon Allybacus as business development manager for

its pre-clinical, clinical and cGMP drug development services. David Tudbury, Business Development Director for Gen-Probe Life Sciences Ltd, said, “We are delighted that Bob and Haroon have joined Gen-Probe. Their proven track records will be a key factor in supporting our growth and expanding our presence in Europe.”